M06.00 Rheumatoid arthritis without rheumatoid factor, unspecified site

Name of the Condition

• Rheumatoid arthritis without rheumatoid factor, unspecified site

Summary

Rheumatoid arthritis without rheumatoid factor (seronegative RA) is a chronic inflammatory disorder affecting joints, characterized by symmetric joint pain, swelling, and stiffness. Unlike seropositive RA, it lacks detectable rheumatoid factor (RF) or anti-citrullinated protein antibodies (ACPA) in blood tests. The condition primarily targets synovial membranes, leading to joint damage over time if untreated. Diagnosis relies on clinical evaluation, imaging, and exclusion of other inflammatory arthritides.

Causes

The exact etiology is unclear but involves a combination of genetic susceptibility and environmental triggers. Immune system dysregulation leads to autoantibody production (excluding RF/ACPA) and chronic joint inflammation. Genetic factors, such as HLA-DRB1 alleles, may increase risk, while smoking or infections may act as triggers. No single cause has been identified.

Risk Factors

• Genetic predisposition (e.g., specific HLA genotypes).
• Female gender (higher prevalence in women).
• Age (onset typically between 30–50 years).
• Smoking, which may influence disease expression.
• Family history of autoimmune disorders.

Symptoms

• Persistent joint pain, swelling, and stiffness, often symmetric.
• Morning stiffness lasting more than 30 minutes.
• Reduced range of motion in affected joints.
• Fatigue and systemic discomfort.
• Possible joint deformities over time.

Diagnosis

Diagnosis requires a combination of clinical assessment, laboratory tests, and imaging. Blood tests exclude RF/ACPA, while inflammatory markers (e.g., ESR, CRP) may be elevated. Imaging (X-rays, MRI) evaluates joint damage. Differential diagnosis includes other inflammatory arthritides (e.g., psoriatic arthritis, lupus) to confirm seronegative RA.

Treatment Options

• Medications: DMARDs (e.g., methotrexate), NSAIDs, or biologics to reduce inflammation.
• Physical Therapy: Exercises to maintain joint function and mobility.
• Lifestyle Adjustments: Weight management and activity modification.
• Surgery: Joint replacement or synovectomy for severe cases.

Prognosis and Follow-Up

Prognosis varies; early treatment improves outcomes by slowing joint damage. Regular follow-ups monitor disease activity, medication efficacy, and complications. Long-term management focuses on symptom control and preventing disability.

Complications

• Joint deformities or erosion.
• Cardiovascular disease (increased risk).
• Lung involvement (e.g., interstitial lung disease).
• Osteoporosis due to chronic inflammation.

Lifestyle & Prevention

• Maintain a balanced diet to support joint health.
• Engage in low-impact exercise (e.g., swimming) to preserve mobility.
• Avoid smoking, which may exacerbate symptoms.
• Use assistive devices (e.g., braces) to reduce joint stress.

When to Seek Professional Help

Seek care if experiencing persistent joint pain, swelling, or stiffness lasting weeks, or if symptoms worsen despite home care. Prompt evaluation is critical to prevent irreversible joint damage.

Tips for Medical Coders

Code M06.00 is used for seronegative RA with unspecified joint involvement. Documentation must confirm the absence of RF/ACPA and specify the affected site (if known). Ensure clinical notes support the diagnosis and exclude other conditions to justify coding.